Iron as a target of chemoprevention for longevity in humans

Free Radical Research

Volumn 45, Issue 8, 2011, Pages 906-917

  Toyokuni, Shinya ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Cancer; Iron; Iron chelator; Neurodegenerative diseases; Phlebotomy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FERROPORTIN 1; HEPCIDIN; IRON; IRON CHELATING AGENT; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SIDEROPHORE;

APOPTOSIS; ATHEROSCLEROSIS; CANCER CELL; CANCER RISK; CARCINOGENICITY; CELL DEATH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG TARGETING; ELECTRON TRANSPORT; GENE DELETION; HEMOCHROMATOSIS; HUMAN; INFECTION; INTRADUCTAL CARCINOMA; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; LONGEVITY; LUNG ADENOCARCINOMA; NEOPLASM; NONHUMAN; OXYGEN AFFINITY; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PHLEBOTOMY; SEPSIS; SIGNAL TRANSDUCTION;

FREE RADICALS; HUMANS; IRON; IRON OVERLOAD; LONGEVITY; NEOPLASMS;

ANIMALIA;

EID: 79960083593     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2011.564170     Document Type: Conference Paper

References (119)

1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056. (Pubitemid 32267975)
2. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Effi-cacy of gefi tinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158. (Pubitemid 37432975)
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno- Jones S, Sawyers CL. Effi cacy and safety of a specifi c inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037. (Pubitemid 32267972)
4. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, Sugiyama Y, Mano H. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893-19897.
5. Hallberg B, Palmer RH. Crizotinib- l atest champion in the cancer wars? N Engl J Med 2010;363:1760-1762.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 2005;353:1673-1684. (Pubitemid 41464706)
7. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, Lo Buglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276. (Pubitemid 29022402)
8. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-1739.
9. Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 2009;9:348-355.
10. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R. Tumor-specifi c idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129-3135.
11. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fi broblasts by defi ned factors. Cell 2007;131:861-872. (Pubitemid 350138099)
12. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother 2007;8:2775-2787. (Pubitemid 350193716)
13. Reddy P, Boci K, Charbonneau C. The epidemiologic, healthrelated quality of life, and economic burden of gastrointestinal stromal tumours. J Clin Pharm Ther 2007;32:557-565. (Pubitemid 350135105)
14. Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol 2008;15:136-142.
15. Zacharski L, Ornstein D, Woloshin S, Schwartz L. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140: 98-104. (Pubitemid 30471247)
16. Wriggleworth JM, Baum H. The biochemical function of iron. In: Jacobs A, Worwood M, editors. Iron in biochemistry and medicine, II. London: Academic Press; 1980. p. 29-86.
17. Fenton HJH. Oxidation of tartaric acid in presence of iron. J Chem Soc 1894;65:899-910.
18. Gutteridge JMC, Rowley DA, Halliwell B. Superoxidedependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts: detection of ' catalytic ' iron and anti-oxidant activity in extracellular fl uids. Biochem J 1982;206:605-609. (Pubitemid 13199533)
19. Thauer R, Jungermann K, Decker K. Energy conservation in chemotrophic anaerobic bacteria. Bacteriol Rev 1977; 41:100-180. (Pubitemid 8082287)
20. Lippard SJ, Berg JM. Principles of bioorganic chemistry. Mill Valley, CA: University Science Books; 1994.
21. Gutteridge JMC. Superoxide-dependent formation of hydroxyl radicals from ferric- complexes and hydrogen peroxide: an evaluation of fourteen iron chelators. Free Radic Res Comm 1990;9:119-125. (Pubitemid 20177140)
22. Graf E, Mahoney JR, Bryant RG, Eaton JW. Iron-catalyzed hydroxyl radical formation: stringent requirement for free iron coordination site. J Biol Chem 1984;259:3620-3624. (Pubitemid 14173396)
23. Toyokuni S, Sagripanti JL. Iron-mediated DNA damage: sensitive detection of DNA strand breakage catalyzed by iron. J Inorg Biochem 1992;47:241-248.
24. Geisser P. Iron therapy: with special emphasis on oxidaitive stress. Stuttgart: Georg Thieme Verlag; 1996.
25. Hopkins CR. Intracellular routing of transferrin and transferrin receptors in epidermoid carcinoma A431 cells. Cell 1983;35:321-330. (Pubitemid 14240243)
26. Hentze M, Kuhn L. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996;93:8175-8182. (Pubitemid 26269529)
27. W heby MS, Jones LG, Crosby WH. Studies on iron absorption. Intestinal regulatory mechanisms. J Clin Invest 1964;43:1433-1442.
28. Gunshin H, Mackenzie B, Berger U, Gunshin Y, Romero M, Boron W, Nussberger S, Gollan J, Hediger M. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-488. (Pubitemid 27328927)
29. Fleming M, Trenor C, Su M, Foernzler D, Beier D, Dietrich W, Andrews N. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997;16:383-386. (Pubitemid 27323306)
30. McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001;291:1755-1759. (Pubitemid 32198974)
31. Fleming M, Romano M, Su M, Garrick L, Garrick M, Andrews N. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 1998;95:1148-1153. (Pubitemid 28124927)
32. Mims M, Guan Y, Pospisilova D, Priwitzerova M, Indrak K, Ponka P, Divoky V, Prchal J. Identifi cation of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005;105:1337-1342. (Pubitemid 40170911)
33. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006;107:349-354. (Pubitemid 43053562)
34. Gunshin H, Fujiwara Y, Custodio A, Direnzo C, Robine S, Andrews N. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005;115:1258-1266. (Pubitemid 40629044)
35. McKie A, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters T, Farzaneh F, Hediger M, Hentze M, Simpson R. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309. (Pubitemid 30628088)
36. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt S, Moynihan J, Paw B, Drejer A, Barut B, Zapata A, Law T, Brugnara C, Lux S, Pinkus G, Pinkus J, Kingsley P, Palis J, Fleming M, Andrews N, Zon L. Positional cloning of zebrafi sh ferroportin1 identifi es a conserved vertebrate iron exporter. Nature 2000;403:776-781. (Pubitemid 30111839)
37. Abboud S, Haile D. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-19912. (Pubitemid 30441595)
38. Shirase T, Mori K, Okazaki Y, Itoh K, Yamamoto M, Tabuchi M, Kishi F, Jiang L, Akatsuka S, Nakao K, Toyokuni S. Suppression of SLC11A2 expression is essential to maintain duodenal integrity during dietary iron overload. Am J Pathol 2010;177:677-685.
39. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-150.
40. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and infl ammation by using ProteinChip System. Blood 2006;108:1381-1387. (Pubitemid 44232041)
41. Nemeth E, Preza G, Jung C, Kaplan J, Waring A, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328-333. (Pubitemid 43053559)
42. Donovan A, Lima C, Pinkus J, Pinkus G, Zon L, Robine S, Andrews N. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005;1:191-200. (Pubitemid 43960600)
43. Akerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta 2000;1482:1-8.
44. Devireddy LR, Hart DO, Goetz DH, Green MR. A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell 2010;141: 1006-1017.
45. Bao G, Clifton M, Hoette TM, Mori K, Deng SX, Qiu A, Viltard M, Williams D, Paragas N, Leete T, Kulkarni R, Li X, Lee B, Kalandadze A, Ratner AJ, Pizarro JC, Schmidt-Ott KM, Landry DW, Raymond KN, Strong RK, Barasch J. Iron traffi cs in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol 2010;6:602-609.
46. Roudkenar MH, Kuwahara Y, Baba T, Roushandeh AM, Ebishima S, Abe S, Ohkubo Y, Fukumoto M. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J Radiat Res (Tokyo) 2007; 48:39-44. (Pubitemid 46219475)
47. Liu Y-T, Shang D-G, Akatsuka S, Ohara H, Dutta KK, Mizushima K, Naito Y, Yoshikawa T, Izumiya M, Abe K, Nakagama H, Noguchi N, Toyokuni S. Chronic oxidative stress causes amplifi cation and overexpresson of ptprz1 protein tyrosine phosphatase to activate-catenin pathway. Am J Pathol 2007;171:1978-1988.
48. Dhaliwal B, Steinbrecher U. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta 1999;286:191-205. (Pubitemid 29406108)
49. Davies MJ, Thomas AC. Plaque fi ssuring-the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985;53:363-373. (Pubitemid 15055510)
50. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-1294. (Pubitemid 11111356)
51. Kirk EA, Heinecke JW, Le Boeuf RC. Iron overload diminishes atherosclerosis in apoE-defi cient mice. J Clin Invest 2001;107:1545-1553. (Pubitemid 32574641)
52. Araujo JA, Romano EL, Brito BE, Parthe V, Romano M, Bracho M, Montano RF, Cardier J. Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995;15:1172-1180.
53. Dabbagh AJ, Shwaery GT, Keaney JF, Frei B. Effect of iron overload and iron defi ciency on atherosclerosis in the hypercholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1997; 17:2638-2645. (Pubitemid 28016003)
54. Niederau C. Iron overload and atherosclerosis. Hepatology 2000;32:672-674.
55. Failla M, Giannattasio C, Piperno A, Vergani A, Grappiolo A, Gentile G, Meles E, Mancia G. Radial artery wall alterations in genetic hemochromatosis before and after iron depletion therapy. Hepatology 2000;32:569-573.
56. Sullivan JL. Iron in arterial plaque: modifi able risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-723.
57. Stadler N, Lindner RA, Davies MJ. Direct detection and quantifi cation of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004;24:949-954. (Pubitemid 38620877)
58. Lee TS, Shiao MS, Pan CC, Chau LY. Iron-defi cient diet reduces atherosclerotic lesions in apoE-defi cient mice. Circulation 1999;99:1222-1229.
59. Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-defi cient mice. J Biomed Sci 2003;10:510-517.
60. Moreno PR, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, Fallon JT, Lento PA, Winterstern A, Levy AP. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008;52:1049-1051.
61. Chen YH, Lin SJ, Lin MW, Tsai HL, Kuo SS, Chen JW, Charng MJ, Wu TC, Chen LC, Ding YA, Pan WH, Jou YS, Chau LY. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002;111:1-8.
62. Chen YH, Chau LY, Chen JW, Lin SJ. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008;31:1615-1620.
63. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood) 2007;232: 1014-1020. (Pubitemid 47358184)
64. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006;26:323-342.
65. Kawai Y, Tanaka H, Murota K, Naito M, Terao J. (-)-Epicatechin gallate accumulates in foamy macrophages in human atherosclerotic aorta: implication in the anti-atherosclerotic actions of tea catechins. Biochem Biophys Res Commun 2008;374:527-532.
66. Kawai Y, Nishikawa T, Shiba Y, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K, Terao J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary fl avonoids. J Biol Chem 2008;283:9424-9434.
67. Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008;6:541-552. (Pubitemid 351863367)
68. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, Sato Y, Fujikawa K, Takahashi M, Takayama T, Ikeda T, Niitsu Y. Normalization of elevated hepatic 8-hydroxy- 2 ' -deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001;61:8697-8702. (Pubitemid 34013879)
69. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y, Takayama T, Niitsu Y. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-836. (Pubitemid 47617461)
70. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008;134:226-238. (Pubitemid 350309316)
71. Pathology of asbestos-associated diseases. In: Roggli VL, Oury TD, Sporn TA, editors. 2nd ed. New York: Springer Verlag; 2004.
72. McDonald A, McDonald J, Pooley F. Mineral fi bre content of lung in mesothelial tumours in North America. Ann Occup Hyg 1982;26:417-422. (Pubitemid 13232245)
73. Jiang L, Nagai H, Ohara H, Hara S, Tachibana M, Hirano S, Shinohara Y, Kohyama N, Akatsuka S, Toyokuni S. Characteristics and modifying factors of asbestos-induced oxidative DNA damage. Cancer Sci 2008;99:2142-2151.
74. Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am J Ind Med 1996;30:252-266. (Pubitemid 26299959)
75. Brinton L, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176:572-579. (Pubitemid 27147164)
76. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997;30:249-255. (Pubitemid 27148154)
77. Yamaguchi K, Mandai M, Toyokuni S, Hamanishi J, Higuchi T, Takakura K, Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the ironinduced persistent oxidative stress. Clin Cancer Res 2008;14: 32-40. (Pubitemid 351377975)
78. Campbell JA. Effects of precipitated silica and of iron oxide on the incidence of primary lung tumours in mice. Br Med J August 1940;31:275-280.
79. Richmond HG. Induction of sarcoma in the rat by irondextran complex. Br Med J 1959;i:947-949.
80. Ebina Y, Okada S, Hamazaki S, Ogino F, Li JL, Midorikawa O. Nephrotoxicity and renal cell carcinoma after use of ironand aluminum- nitrilotriacetate complexes in rats. J Natl Cancer Inst 1986;76:107-113. (Pubitemid 16156111)
81. Li JL, Okada S, Hamazaki S, Ebina Y, Midorikawa O. Subacute nephrotoxicity and induction of renal cell carcinoma in mice treated with ferric nitrilotriacetate. Cancer Res 1987;47:1867-1869. (Pubitemid 17056692)
82. Toyokuni S, Okada S, Hamazaki S, Minamiyama Y, Yamada Y, Liang P, Fukunaga Y, Midorikawa O. Combined histochemical and biochemical analysis of sex hormone dependence of ferric nitrilotriacetate-induced renal lipid peroxidation in ddY mice. Cancer Res 1990;50: 5574-5580. (Pubitemid 20303021)
83. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenalmodifi ed proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 1994;91:2616-2620. (Pubitemid 24139398)
84. Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Ochi H, Hiai H, Uchida K, Osawa T. Quantitative immunohistochemical determination of 8-hydroxy-2 ' -deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate- induced renal carcinogenesis model. Lab Invest 1997;76:365-374. (Pubitemid 27157344)
85. T oyokuni S, Luo XP, Tanaka T, Uchida K, Hiai H, Lehotay DC. Induction of a wide range of C2-12 aldehydes and C7-12 acyloins in the kidney of Wistar rats after treatment with a renal carcinogen, ferric nitrilotriacetate. Free Radic Biol Med 1997;22:1019-1027. (Pubitemid 27084139)
86. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989;60:708-711. (Pubitemid 19275735)
87. Nishiyama Y, Suwa H, Okamoto K, Fukumoto M, Hiai H, Toyokuni S. Low incidence of point mutations in H-, K- and N-ras oncogenes and p53 tumor suppressor gene in renal cell carcinoma and peritoneal mesothelioma of Wistar rats induced by ferric nitrilotriacetate. Jpn J Cancer Res 1995;86: 1150-1158.
88. Toyokuni S, Mori T, Dizdaroglu M. DNA base modifi cations in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer 1994;57:123-128. (Pubitemid 24117111)
89. Toyokuni S, Mori T, Hiai H, Dizdaroglu M. Treatment of Wistar rats with a renal carcinogen, ferric nitrilotriacetate, causes DNA-protein cross-linking between thymine and tyrosine in their renal chromatin. Int J Cancer 1995;62:309-313.
90. Jiang L, Zhong Y, Akatsuka S, Liu Y, Dutta K, Lee W, Onuki J, Masumura K, Nohmi T, Toyokuni S. Deletion and single nucleotide substitution at G:C in the kidney of gpt delta transgenic mice after ferric nitrilotriacetate treatment. Cancer Sci 2006;97: 1159-1167. (Pubitemid 44430641)
91. Tanaka T, Iwasa Y, Kondo S, Hiai H, Toyokuni S. High incidence of allelic loss on chromosome 5 and inactivation of p15 INK4B and p16 INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 1999;18:3793-3797. (Pubitemid 29338514)
92. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-8297. (Pubitemid 28326106)
93. Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-27. (Pubitemid 29005019)
94. Hiroyasu M, Ozeki M, Kohda H, Echizenya M, Tanaka T, Hiai H, Toyokuni S. Specifi c allelic loss of p16 INK4A tumor suppressor gene after weeks of iron-mediated oxidative damage during rat renal carcinogenesis. Am J Pathol 2002; 160:419-424. (Pubitemid 34160318)
95. Akatsuka S, Aung TT, Dutta KK, Jiang L, Lee WH, Liu YT, Onuki J, Shirase T, Yamasaki K, Ochi H, Naito Y, Yoshikawa T, Kasai H, Tominaga Y, Sakumi K, Nakabeppu Y, Kawai Y, Uchida K, Yamasaki A, Tsuruyama T, Yamada Y, Toyokuni S. Contrasting genome-wide distribution of 8-hydroxyguanine and acrolein-modifi ed adenine during oxidative stress-induced renal carcinogenesis. Am J Pathol 2006;169:1328-1342. (Pubitemid 351194367)
96. Ottolenghi A, Joseph L, Newman H, Stephens R. Interaction of erythrocyte membranes with particulates. Environ Health Perspect 1983;51:253-256. (Pubitemid 14240828)
97. Lee W, Testa J. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol 1999;14:181-188.
98. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, Takahashi T, Toyokuni S. Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010;90:360-373.
99. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1-3.
100. Meerlo P, Mistlberger RE, Jacobs BL, Heller HC, McGinty D. New neurons in the adult brain: the role of sleep and consequences of sleep loss. Sleep Med Rev 2009;13:187-194.
101. Bradbury MW. Transport of iron in the blood-brain-cerebrospinal fl uid system. J Neurochem 1997;69:443-454. (Pubitemid 27327945)
102. Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, Biemba G, Msiska R, Holme L, McKinley E, Vargas L, Gilkeso R, Poltera AA. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473-1477.
103. Butensky E, Kennedy CM, Lee MM, Harmatz P, Miaskowski C. Potential mechanisms for altered iron metabolism in human immunodefi ciency virus disease. J Assoc Nurses AIDS Care 2004;15:31-45. (Pubitemid 44069569)
104. Taylor TD, Litt M, Kramer P, Pandolfo M, Angelini L, Nardocci N, Davis S, Pineda M, Hattori H, Flett PJ, Cilio MR, Bertini E, Hayfl ick SJ. Homozygosity mapping of Hallervorden- Spatz syndrome to chromosome 20p12.3-p13. Nat Genet 1996;14:479-481. (Pubitemid 26414596)
105. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayfl ick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349. (Pubitemid 32702423)
106. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology 2003;23:345-350. (Pubitemid 38004869)
107. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004;1012:193-208. (Pubitemid 38455479)
108. Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 2004;1012:14-26. (Pubitemid 38453512)
109. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, Bush AI. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010;142:857-867.
110. Becker E, Richardson D. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia. Int J Biochem Cell Biol 2001;33:1-10. (Pubitemid 32146462)
111. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R, Van Rhee F, Barlogie B, Anaissie EJ. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006;37:857-864.
112. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547-583. (Pubitemid 43036441)
113. Zacharski L, Chow B, Howes P, Shamayeva G, Baron J, Dalman R, Malenka D, Ozaki C, Levori P. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002. (Pubitemid 352019800)
114. Edgren G, Nyren O, Melbye M. Cancer as a ferrotoxic disease: are we getting hard stainless evidence? J Natl Cancer Inst 2008;100:976-977. (Pubitemid 352019803)
115. Edgren G, Reilly M, Hjalgrim H, Tran T, Rostgaard K, Adami J, Titlestad K, Shanwell A, Melbye M, Nyren O. Donation frequency, iron loss, and risk of cancer among blood donors. J Natl Cancer Inst 2008;100:572-579.
116. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-566. (Pubitemid 26097272)
117. Wu T, Sempos C, Freudenheim J, Muti P, Smit L. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201. (Pubitemid 38249333)
118. Zacharski L, Chow B, Howes P, Shamayeva G, Baron J, Dalman R, Malenka D, Ozaki C, Lavori P. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA 2007;297:603-610.
119. Nishida Y, Yoshizawa K, AKamatsu T. Preparation of iron(III) comple with nitrilotriacetic acid and origin of its unique reactivity. Chem Lett 1991;20:1521-1524.